Home / Archive / September 2020

September 2020 Volume 16, Issue 8

Volume 16, Issue 8 | September 2020

In this Issue

Clinical Trials

Mighty micro PEA

Prospective COVID-19 treatment uses cannabinoid approach

In pursuit of emergency authorization

RedHill Biopharma accelerates Phase 2/3 COVID-19 drug opaganib program

ISA101b and Libtayo vs. oropharyngeal cancer

ISA Pharmaceuticals strengthens strategic immuno-oncology collaboration with Regeneron

Research highlights potential of Akero’s NASH candidate

Patients treated with efruxifermin show improvements in markers of insulin sensitivity and lipoprotein metabolism

Hopes on the rise in wake of ASCENT data

Immunomedics shares strong data for Trodelvy in triple-negative breast cancer

Discovery

Quantum (computing) gains

Drug discovery expected to be one of the first beneficiaries of technology

Where AI meets biology

TARA and VentAI collaborate on drug discovery

Human-on-a-Chip system models Alzheimer’s

Publication validates potential of drug discovery platform to study early stages of disease pathology

An ‘exquisitely selective’ tool

Mission Therapeutics and Imperial College London report on deubiquitylating enzyme probe

Welcoming the fourth wave of drug discovery

Amgen executive forecasts multispecific drugs as the next key movement

Business & Government Policy

Q&A: Another look at aducanumab

ProMIS Neurosciences’ CMO talks with DDN about why Biogen restarted its Alzheimer’s disease program

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Interplay between obviousness and satisfaction invalidates claims in Biogen Tecfidera patent

The same evidence that supports non-obviousness for patentability can also restrict the scope of what has been described

Research & Development

Gaining ground with Gemini

In-silico patient model moves industry a step closer to understanding human disease

Leveraging lentivirals

Magenta Therapeutics joins with AVROBIO to evaluate a combination approach to gene therapy

Orchard and GSK announce license agreements

New agreements will benefit patients with WAS and TDT

Tracking down gene fusions

Stanford researchers use single-cell statistical modeling method to go after cancer

Contract Services

A faster new product pathway

LGM Pharma acquires Nexgen Pharma’s CDMO operations

Integrated services for COVID and more

CaprionX-HistoGeneX and Viroclinics-DDL to offer complementary services for infectious disease research and therapeutics

Mid-Size CRO steps up

Pharm-Olam positioning organization for growth trajectory

Diagnostics

Exhaled biomarkers reveal lung disease

Nanoparticles create a ‘breath signal’ that could be used to diagnose infectious or genetic diseases

Antigens for SARS-CoV-2

LGC acquires NAC, one of first to offer antigens for novel coronavirus

Critical for cancer

U.K.-Italy collaboration aims for precision oncology at scale

Trying to meet coronavirus demands

NIH awards nearly $249M into new COVID-19 testing technologies

Preclinical

Can a vaccine prevent type 1 diabetes?

Provention Bio advances work on coxsackievirus B vaccine

A (natural) killer match

Kiadis, Sanofi ink license agreement for natural killer therapeutics

Editor's Focus

Editor’s Focus: Alzheimer’s looms large in neuroscience

Market research suggests that neurology-related pharma and biotech R&D is going to be dominated by Alzheimer's disease for some time

Commentary

Innovating scientific conferences

More meetings are going virtual, and that may very well be a good thing even after COVID is no longer a pandemic

Guest Commentary: Automation software improves speed and accuracy of cell line production

Innovative lab software automates scheduling, hit-picking and liquid transfer to boost walkaway time

Special Reports

Special Report on Stem Cells: Mother lode

Are cancer stem cells a better oncology target?

Feature

The Society for Nueroscience meeting may have been called off this year, but DDN has a large roundup of recent news of neurological R&D to share in its place, from aging insights via sea urchins to machine learning advances to putting antibodies to work in treating neurodegeneration (and more)